Project Grant R43HL142407

The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel oral small molecule therapeutics for the treatment of progressive pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). The goal is to create a safer and more effective therapy compared to the currently approved drugs, which only slow disease progression and have significant side effects. Novomedix will...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...

The National Heart Lung and Blood Institute awarded a $247,500 Project Grant to The General Hospital Corporation (doing business as Massachusetts General Hospital) to validate a CD206-targeted PET imaging probe for tracking pulmonary fibrosis progression in idiopathic pulmonary fibrosis (IPF) patients. IPF is a chronic, debilitating lung disease with limited treatment options and poor prognosis. The goal is to develop an innovative PET imaging agent that can specifically target CD206-positive...

The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), awarded a $309,418 Project Grant to Oleolive, Inc. to develop an inhaled therapy for idiopathic pulmonary fibrosis (IPF). The award, made on September 20, 2025, will support research to repurpose the FDA-approved drug pyrvinium as an inhalation treatment for IPF, a fatal lung disease affecting 40,000 U.S. patients annually. The project aims to...

This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $284,699 to Aqualung Therapeutics, Corp, a biotechnology company, to optimize the dosage and evaluate the efficacy of their novel ALT-100 monoclonal antibody therapy in preclinical mouse models of lung fibrosis. The goal is to demonstrate the ability of ALT-100 to slow the progression of idiopathic pulmonary fibrosis (IPF), a severe and often...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $542,402 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to a research partnership between Henry Ford Health and Michigan State University Health Sciences. The grant aims to identify drug compounds that can reverse profibrotic gene expression patterns in idiopathic pulmonary fibrosis (IPF), a debilitating lung disease with limited treatment options. Through a sub-award, Corewell Health will provide IPF...

This R01 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $596,179 over a 5-year period beginning on January 1, 2025 to conduct research on the role of macropinocytosis, a cellular process, in the development of pulmonary fibrosis. The research aims to determine whether inhibiting macropinocytosis can attenuate fibrosis in animal models and cell culture systems, as well as elucidate the molecular mechanisms by...

This Project Grant award of $1,410,668 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to investigate the mechanistic roles of cyclin-dependent kinase 9 (CDK9) in idiopathic pulmonary fibrosis (IPF) and validate CDK9 as a new anti-inflammatory and anti-fibrotic pharmacotherapeutic target for treating IPF. The research is being conducted by The Methodist Hospital Research Institute in Houston, Texas, with a sub-award to the University of...

This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $695,421 to The Regents of the University of California, San Francisco (UCSF) to conduct research on reversing the pathogenic remodeling observed in idiopathic pulmonary fibrosis (IPF). The project aims to define pro-reparative differentiation pathways in both the fibroblast and stem cell compartments that can be leveraged as a therapy. Key objectives include: Tracing...